Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.3.1197

Prognostic Implications for High Expression of MiR-25 in Lung Adenocarcinomas of Female Non-smokers  

Xu, Fang-Xiu (Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer)
Su, Yu-Liang (Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer)
Zhang, Huan (Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer)
Kong, Jin-Yu (Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer)
Yu, Herbert (Epidemiology Program, University of Hawaii Cancer Center)
Qian, Bi-Yun (Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.3, 2014 , pp. 1197-1203 More about this Journal
Abstract
Background: Adenocarcinoma (ADC) is the most common histological type of lung cancer and its proportion is rising, especially in Asian non-smoking women. Recent studies suggest miR-25 may have diverse effects on the pathogenesis of different types of cancer. However, the role of miR-25 in lung cancer is still unknown. The aim of this study was to investigate the potential clinical value of miR-25 in non-smoking women with lung ADC. Patients and Methods: Quantitative RT-PCR was performed to evaluate the expression of miR-25 in 100 lung ADC tumor tissues and matched plasma samples and Pearson correlation tests were used to analyze the relationship between values. Associations of miR-25 expression with clinicopathological features were determined using the Student's t-test. To determine prognostic value, overall survival (OS) was evaluated using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazard model. Results: Expression of miR-25 in tissue was found to be associated with lymph node metastasis (P=0.021) and disease stage (P=0.012). Moreover, high miR-25 expression was also associated with poorer overall survival of women with lung ADC (P=0.008). Conclusion: Tissue miR-25 expression may be associated with tumor progression and have prognostic implications in female lung ADC patients.
Keywords
miR-25; lung adenocarcinoma (ADC); prognosis; lymph node metastasis; disease stage;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Salmena L, Carracedo A, Pandolfi P P (2008). Tenets of PTEN tumor suppression. Cell, 133, 403-14.   DOI   ScienceOn
2 Qiang L, Zou C, Zou C, et al (2013). MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Letters, 335, 168-74.   DOI   ScienceOn
3 Raben D, Helfrich B, Bunn P A, Jr. (2004). Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys, 59, 27-38.   DOI   ScienceOn
4 Rudin C M, Avila-Tang E, Harris C C, et al (2009). Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res, 15, 5646-61.   DOI   ScienceOn
5 Scapoli L, Palmieri A, Lo Muzio L, et al (2010). MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol, 23, 1229-34.
6 Shen J, Todd N, Zhan H, et al (2011 ). Plasma microRNAs as potential biomarkers for non-small-cell lung cancer.Lab Invest, 91, 579-87.   DOI   ScienceOn
7 Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.   DOI   ScienceOn
8 Suh SS, Yoo JY, Nuovo GJ, et al (2012). MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA, 109, 5316-21.   DOI
9 Toh C K, Gao F, Lim W T, et al (2006). Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol, 24, 2245-51.   DOI   ScienceOn
10 Toh CK, Lim WT (2007). Lung cancer in never-smokers. J Clin Pathol, 60, 337-40.
11 Manning BD, Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell, 129, 1261-74.   DOI   ScienceOn
12 Liu N, Chen NY, Cui RX, et al (2012). Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol, 13, 633-41.   DOI   ScienceOn
13 Li Y, Tan W, Neo TW, et al (2009). Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci, 100, 1234-42.   DOI   ScienceOn
14 Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.   DOI   ScienceOn
15 Pallis AG, Syrigos KN (2013). Lung cancer in never smokers: Disease characteristics and risk factors. Crit Rev Oncol Hematol, 88, 494-503.   DOI   ScienceOn
16 Metayer C, Wang Z, Kleinerman R A, et al (2002). Cooking oil fumes and risk of lung cancer in women in rural Gansu, China. Lung Cancer, 35, 111-7.   DOI   ScienceOn
17 Min K, Li Y, Liu W, et al (2013 ). miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression.Int J Mol Med 32, 51-8.
18 Myong NH (2004). Reduced expression of E-cadherin in human non-small cell lung carcinoma.Cancer Res Treat, 36, 56-61.   DOI   ScienceOn
19 Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Current Issue, 101, 13306-11
20 Poliseno L, Salmena L, Riccardi L, et al (2010). Identification of the miR-106b-25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its HostGene MCM7 in Transformation. Sci Signal, 3, 1-26.
21 Ciuffreda LMJ, Milella M (2009). Signaling intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK pathways) as therapeutic targets for anti-cancer and anti angiogenesis treatments. Curr Signal Transduct Ther, 4, 130-43.   DOI
22 Calin GA, Croce CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6, 857-66.   DOI   ScienceOn
23 Chen Q, Si Q, Xiao S, et al (2013). Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol, 30, 353.   DOI   ScienceOn
24 Franchina T, Amodeo V, Bronte G, et al (2013). Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. J Cell Physiol, 229, 97-9.
25 Ciuffreda L, Di Sanza C, Cesta Incani U, et al (2012). The mitogen-activated protein kinase (MAPK) cascadecontrols phosphatase and tensin homolog (PTEN)expression through multiple mechanisms. J Mol Med, 90, 667-79.   DOI   ScienceOn
26 Dacic S, Kelly L, Shuai Y, Nikiforova MN (2010). miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol, 2 3, 1577-82.   DOI   ScienceOn
27 Esposito F, Tornincasa M, Pallante P, et al (2012). Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab, 97, 710-8.   DOI   ScienceOn
28 Garofalo M, Jeon YJ, Nuovo GJ, et al (2013). MiR-34a/c-Dependent PDGFR-alpha/beta Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS One, 8, 675-81.
29 Lewis BP, Shih IH, Jones-Rhoades MW, et al (2003). Prediction of mammalian microRNA targets.Cell, 115, 787-98.   DOI   ScienceOn
30 Bartel DP(2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.   DOI   ScienceOn
31 Besson A, Dowdy SF, Roberts JM (2008). CDK inhibitors: cell cycle regulators and beyond. Dev Cell, 14, 159-69.   DOI   ScienceOn
32 Yang L, Tan W, Neo T, et al (2009). Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci, 100, 1234-42.   DOI   ScienceOn
33 Zhu W, Liu X, He J, et al (2011b). Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: A case control study. BMC Cancer, 11, 392-402.   DOI
34 Yeh Y, Chuang C, Chao K, Wang L ( 2013). MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1. Int J Cancer, 133, 867-78.   DOI   ScienceOn
35 Zhang H, Zuo Z, Lu X, et al (2012). MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer.Oncol Rep, 27, 594-8.
36 Zhu L, Yan W, Rodriguez-Canales J, et al (2011a). MicroRNA analysis of microdissected normal squamous esophageal epithelium and tumor cells. Am J Cancer Res, 1, 574-84.
37 Wu X, Ajani J A, Gu J, et al (2013). MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila), 6, 196-205.   DOI   ScienceOn
38 Volinia S, Calin GA, Liu CG, et al (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA, 103, 2257-61.   DOI   ScienceOn
39 Wakelee HA, Chang ET, Gomez SL, et al (2007). Lung cancer incidence in never smokers. J Clin Oncol, 25, 472-8.   DOI   ScienceOn
40 Wang Y, Li Z, He C, et al (2010). MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis, 44, 191-7.   DOI   ScienceOn
41 Xu X, Chen Z, Zhao X, et al (2012). MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun, 421, 640-5.   DOI   ScienceOn
42 Yang K, Zhao W, Xiong J, Cao R (2013). Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett, 587, 3153-7.   DOI   ScienceOn
43 Kim B H, Hong S W, Kim A, et al (2013). Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol, 107, 505-10.   DOI   ScienceOn
44 Thun MJ, Hannan LM, Adams-Campbell LL, et al (2008). Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med, 5, e185.   DOI   ScienceOn